U.S. experts had a difficult series of decisions to make about boosters based on limited data. But it’s hard to say their final advice is clear, evidence-based or in the best interests of public health.
By Max Nisen | Bloomberg, Washington Post: Business
Fri, 09/24/2021 - 12:53am
U.S. experts had a difficult series of decisions to make about boosters based on limited data. But it’s hard to say their final advice is clear, evidence-based or in the best interests of public health.